BioCryst surges on upbeat PhII gout data; IDEXX buys research/lab in $43M deal;

 @FierceBiotech: Blockbuster breakup: Amylin buys out Lilly's exenatide rights in $1.6B deal. News | Follow @FierceBiotech

 @JohnCFierce: Key AZ/Targacept depression drug flunks first Phase III test. Item | Follow @JohnCFierce

 @RyanMFierce: Medidata (SaaS clinical trials software) reports profits up in 3Q, 33 new customers, $MDSO up 2.04%. Release | Follow @RyanMFierce

 @MaureenFierce: Nabi will explore strategic options after its anti-smoking vaccine NicVAX failed in a second Phase III trial. Article | Follow @MaureenFierce

> Shares of BioCryst Pharmaceuticals surged on positive mid-stage results for its experimental gout therapy. The results set the stage for a Phase III program. Report

> IDEXX Laboratories has struck a deal to buy a research and diagnostic lab business from the University of Missouri for $43 million. Report

> NeurogesX announced positive top-line results from its Phase II clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia. Release

> Insmed reported that the clinical hold on its late-stage lung drug spurred a bigger-than-expected loss for the last quarter. Story

Pharma News

 @FiercePharma: Integrating Cephalon, Teva eyes up to 1,500 job cuts. News | Follow @FiercePharma

> Key antidepressant from AZ/Targacept fails trial. Report

> AZ launches Crestor co-pay card to battle. Story

> Lipitor copies Amid FCPA probe, AZ indicted in Serbia for bribery. Article

Biotech Research News

> Eliminating 'senescent' cells in mice delayed age-related ailments. News

> Stem cell therapy for Parkinson's works wells in two animal models. Story

> Scripps breakthrough unlocks the potential of a promising cancer drug class. More

Manufacturing News

> Plant check reveals Genentech report flaw repeat. Article

> Pharma recalls up 54% in Q3. Item

> MedImmune cell-culture plant named facility of the year. Story

And Finally... Investigators at three sites in the U.S. are studying an experimental retroviral gene therapy from Tocagen for glioblastomas. Story

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.